Finally, one of the major problems was funding. 5 There are few provisions from within the National Health Service for providing support groups but a charitable group associated with the hospital generously agreed to provide support for food and refreshments for the first few meetings until alternative arrangements were made. Funds are also required for guest speakers and to provide travel support for our dispersed patient group. The patients have also been seeking funding and a number of pharmaceutical companies have agreed to provide financial support.
In summary, the setting up of a BMT support group requires a lot of work and the duties are best shared among professionals of multiple disciplines. A 'democratic' approach of asking what BMT patients wanted appears to have been successful. Initial feedback from the first two meetings has been extremely encouraging; we plan to continually revise our aims and evaluate our efficacy by further surveys and questionnaires.
Engraftment syndrome after autologous peripheral blood stem cell transplantation with high numbers of peripheral blood stem cells followed by granulocyte colonystimulating factor administration
Autologous peripheral blood stem cell transplantation (PBSCT) is characterized by rapid hematological recovery. Clinical studies have shown a direct relationship between the numbers of colony-forming unit granulocyte-macrophage (CFU-GM) or CD34 + cells in leukapheresis products and leukocyte recovery. 1 The numbers of 1 to 2 × 10 5 /kg CFU-GM or 1 to 2 × 10 6 CD34 + cells/kg are generally agreed as the minimum threshold for adequate hematopoietic reconstitution. 1 Although there seems to be an upper threshold at 5 × 10 5 CFU-GM/kg or 5 × 10 6 CD34 + cells/kg, 1 patients receiving autologous PBSCT with a CD34 + cell dose у5 × 10 6 /kg have a reduced demand for red cell and platelet transfusions, a reduction in the use of antibiotics, and short periods of hospitalization. 2 However, adverse effects of the infusion of high numbers of peripheral blood stem cells followed by granulocyte colonystimulating factor (G-CSF) administration have not been well examined. We wish to report a patient with engraftment syndrome caused by autologous PBSCT followed by G-CSF treatment.
A 49-year-old female with acute lymphoblastic leukemia in fourth complete remission was admitted to the Jichi Medical School to receive autologous PBSCT in May 1999. She was heavily treated before entering complete remission. Peripheral blood stem cells had been collected using an automated continuous-flow blood cell separator (Spectra; Cobe, Engelwood, CO, USA) after two courses of high-dose cytarabine followed by G-CSF administration. A total of 70 × 10 ) as conditioning regimen. Peripheral blood stem cells were rapidly thawed and infused via a central venous line. On the next day, 300 g/m 2 of G-CSF (filgrastim) was given i.v. to enhance rapid hematological recovery. On day +5, bone pain and fever occurred. Chest X-rays showed no evidence of pneumonia. Antibiotics were changed and fluconazole was added. As shown in Figure 1 , on day +7 the leukocyte count reached 3.7 × 10 9 /l (neutrophil, 1.1 × 10 9 /l). On day +8, the leukocyte count was 28.4 × 10 9 /l and G-CSF administration was terminated. On the same day, the patient complained of dyspnea. Arterial oxygen saturation measured by pulse oximetry was 91% without oxygen supplementation. Chest X-ray demonstrated bilateral patchy alveolar densities diffusely distri-buted over both lungs, consistent with acute respiratory distress syndrome. No pathological bacteria or fungi were detected in sputa. Cytomegalovirus antigenemia was negative. She gained weight associated with hypoalbuminemia (2.8 g/dl). No skin rash was observed. The patient was diagnosed as having engraftment syndrome. A dose of 1 g/day of methylprednisolone (mPSL) was administered i.v. from days +8 to +10, and then the dose was tapered off. Despite the cessation of G-CSF administration, the leukocyte count progressively increased to a maximum of 87.3 × 10 9 /l (neutrophil, 73.2 × 10 9 /l) on day +14. Platelet recovery was slower than leukocyte recovery. After bolus mPSL therapy, symptoms and signs of respiratory impairment disappeared. On day +19, chest X-rays showed no abnormal shadows in either lung.
Complications such as non-infectious fever, skin rashes, fluid retention and pulmonary interstitial infiltrates associated with a rapid increase in neutrophil recovery after autologous blood stem cell transplantation are known as engraftment syndrome. 3, 4 The syndrome is closely associated with G-CSF administration after autologous blood stem cell transplantation. 4, 5 Pneumonitis is radiologically characterized by pulmonary interstitial infiltrates. G-CSF causes pneumonitis in patients who receive chemotherapy plus G-CSF. 6 The mechanism of G-CSF-induced pneumonitis remains to be clarified. Chemotherapy plus G-CSF but not G-CSF alone causes pneumonitis in patients. 6 G-CSF activates neutrophil functions 7 and induces interleukin-6 production from neutrophils. 8 These observations suggest that activated neutrophils induced by G-CSF exert deleterious effects on subclinical lung damage produced by anti-cancer agents. Our patient was heavily treated before receiving pretransplant conditioning and she received a lung-toxic agent, busulfan, as pretransplant conditioning. Therefore, it is possible that since the patient had subclinical lung damage, she suffered from pneumonitis induced by G-CSF.
The role of G-CSF use after autologous PBSCT is somewhat controversial. Early G-CSF administration after autologous PBSCT results in overall cost savings per transplant. 9 However, the clinical benefit of G-CSF administration after autologous PBSCT is only one day earlier recovery of neutrophils. 10 Therefore, we suggest that in the infusion of over 10 × 10 5 CFU-GM/kg or 10 × 10 6 CD34 + cells/kg, G-CSF should not be administered to patients heavily treated before receiving pretransplant conditioning in order to avoid engraftment syndrome. 
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